Aurigene Discovery Technologies Limited
Privately held: no public share price
Assets
(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | IRAK4Small molecule | Acute Myeloid LeukemiaNon-Hodgkin Lymphoma Relapsed/Refractory Acute Myeloid Leukemia, Primary Central Nervous System Lymphoma | |
| Phase 1 | CBP/p300 (bromodomain)Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
July 2027 (1)
EmavusertibPhase 1/2Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma …
Est. primary completion 2027-07 · NCT03328078 · CT.gov ↗
What to watch
November 2027 (1)
Est. primary completion 2027-11 · NCT07271667 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.